Evolus, Inc. (EOLS) News
Follow Evolus, Inc. (EOLS) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 6 public stories across 5 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
L
Evolus CEO sold common shares worth over $950K
Evolus President and CEO David Moatazedi reported a direct sale of common stock on 2026-09-02. The filing shows multiple trades priced $9.00 to $9.13, with a weighted average $9.0385 per share.
EQUITY | Sep 04, 2026, 11:10 PM UTC
L
A Wave of Weight-Loss Drugs Is Quietly Creating a Multi-Billion-Dollar Opportunity That Aesthetic Medicine Is Racing to Capture
NEW YORK, Sept. 1, 2026 /CNW/ -- Equity Insider News Commentary - The global medical aesthetics market has quietly become one of the most durable growth stories in healthcare. Multiple market-research firms size it at ro
FX | Sep 01, 2026, 03:38 PM UTC
L
America Fell in Love With Filler. Then Came the Great Deflate — WSJ
America Fell in Love With Filler. Then Came the Great Deflate — WSJ
EQUITY | Aug 31, 2026, 06:40 PM UTC
L
EOLS - Evolus Reports Strong Second Quarter 2026 Financial Results; Delivers Third Consecutive Quarter of Positive Adjusted EBITDA and Raise
EOLS - Evolus Reports Strong Second Quarter 2026 Financial Results; Delivers Third Consecutive Quarter of Positive Adjusted EBITDA and Raises Full-Year 2026 Financial Outlook
EARNINGS | Aug 05, 2026, 08:16 PM UTC
L
Evolus Raises FY2026 Sales Guidance from $327.000M-$337.000M to $330.000M-$337.000M vs $330.445M Est
Evolus (NASDAQ: EOLS ) raises FY2026 sales outlook from $327.000 million-$337.000 million to $330.000 million-$337.000 million vs $330.445 million estimate.
EARNINGS | Aug 05, 2026, 08:09 PM UTC
M
Evolus Expands Partnership with Symatese
Evolus expands partnership to commercialize Estyme
EQUITY | Aug 04, 2026, 12:33 PM UTC